Actuate Therapeutics, Inc. (ACTU) · Oct 30, 2026 · Delisting
Bid-price deficiency — Below $1.00 for 30 consecutive business days; cure by April 26, 2027
Actuate’s Nasdaq delisting notice adds a $1 bid-price deadline while its earlier MVLS deficiency remains unresolved, raising the listing risk around its clinical program.
Actuate is a clinical-stage biopharma developing elraglusib for difficult-to-treat cancers, while advancing an oral formulation and new Phase 1/2 work in advanced solid tumors. This filing adds a second listing problem to an already constrained story. Nasdaq says Actuate’s stock closed below the $1.00 minimum bid price for 30 consecutive business days, creating a new 180-day cure period through April 26, 2027. There is no immediate delisting, but the company now has two separate compliance clocks. The earlier market-value deficiency still runs until January 11, 2027, while the new bid-price issue can require at least 10 consecutive business days above $1.00 by April 26, 2027. 〔0〕 The practical risk is higher than a routine warning because failure could force a market transfer or delisting. Actuate may seek a second 180-day period by moving to Nasdaq’s Capital Market, but that depends on meeting other listing standards; the filing gives no assurance it can do so. 〔1〕 Bottom line: This does not interrupt the drug program today, but it materially complicates the financing and public-market platform supporting it. The notice is new, and it compounds an unresolved MVLS deficiency rather than merely confirming a scheduled administrative step.
MVLS compliance deadline, January 11, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!